<DOC>
	<DOCNO>NCT01011231</DOCNO>
	<brief_summary>The purpose study ass efficacy , treat patient recurrent glioblastoma use Gamma-Knife Radiosurgery ( GKS ) target tumor volume define combination gadolinium enhancement magnetic resonance spectroscopy ( MRS ) . This single center , Phase II trial . A total 40 glioblastoma patient enrol primary arm trial . In addition , minimum 10 patient recurrent anaplastic ( grade III ) gliomas minimum 10 patient recurrent low-grade ( grade II ) glioma enrol exploratory arm . The investigator hypothesize use combination gadolinium enhancement elevate Cho : NAA ratio via MRS determine treatment target volume Gamma Knife may effective way treat focally-recurrent glioblastoma .</brief_summary>
	<brief_title>Study Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging ( MRI ) Spectroscopy Recurrent Glioma</brief_title>
	<detailed_description>Study Design : A single-center , single-arm , one-stage phase II clinical trial patient recurrent grade IV glioma ( glioblastoma ) , two additional exploratory arm patient recurrent grade II grade III glioma . Patient Numbers : A total 40 patient recurrent glioblastoma enrol . In addition , minimum 10 patient recurrent grade III ( anaplastic ) glioma minimum 10 patient recurrent grade II ( low-grade ) glioma enrol independently separate exploratory arm . Summary Patient Eligibility Criteria Histological confirmation glioma , grade II - IV ; prior first-line treatment surgery , radiotherapy chemotherapy malignant ( grade III IV ) glioma ; age &gt; 18 year ; life expectancy &gt; 8 week ; Karnofsky Performance Status ≥ 60 ; adequate organ function ; sign patient inform consent ; willingness forego additional therapy evidence disease progression . End Points Primary : Six-month progression-free survival ( PFS-6 ) Secondary : Median overall survival ( mOS ) , median progression-free survival ( mPFS ) , location recurrence , symptomatic necrosis rate , reoperation rate , reoperation finding ( estimate percentage viable tumor vs. radiation effect necrosis ) , safety</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Histologically confirm glioblastoma , gliosarcoma , anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma , malignant glioma otherwise specify , lowgrade astrocytoma , lowgrade oligodendroglioma , lowgrade oligoastrocytoma , lowgrade glioma otherwise specify . 2 . Prior firstline treatment surgery biopsy follow fractionated radiotherapy concurrent temozolomidecontaining chemotherapy require malignant ( grade III IV ) glioma patient . Additional prior chemotherapy allow , without limitation number recurrence . In patient lowgrade tumor , neither prior radiotherapy prior chemotherapy require . 3 . An interval &gt; 2 month since completion fractionate radiotherapy . 4 . Age &gt; 18 year 5 . Life expectancy least 8 week . 6 . Karnofsky Performance Status score ( KPS ) ≥ 60 7 . Documented recurrent disease : Recurrent disease define either histological confirmation tumor , increase tumor size least 25 % base upon serial MR image , development new site disease . Tumor size calculate use sum large crosssectional perpendicular diameter contrastenhancing tumor highgrade tumor , sum large crosssectional perpendicular diameter FLAIR abnormality lowgrade tumor , worsen spectroscopic characteristic tumor type ( development ≥ 2 new voxels CNI ≥ 3 , ≥ 25 % increase sum CNI ratio within group previously abnormal voxels [ abnormal define CNI ≥ 3 ] ) . Disease must evaluable , need measurable . The target site GKS need locate previouslyirradiated area . 8 . Eligibility gammaknife radiosurgery : The decision treat gammaknife radiosurgery make consensus radiation oncology , neurosurgery neurooncology cochairs alternate weekly Brain Tumor GammaKnife Tumor Conferences . The MRS define target volume must ≤ 15 cc . involve eloquent brain ( speech/language cortex , motor/sensory cortex , basal ganglion , brainstem , corpus callosum 2 ) MRI do within 14 day plan GKS procedure . 9 . BUN &lt; 25 Cr &lt; 1.7 10 . Negative pregnancy test time GKS patient could pregnant . 11 . Willingness forego additional therapy evidence disease progression . 12 . Signed witness informed consent sign authorization release protect health information . 1 . MRS define tumor volume great 15 cc . 2 . MRS define tumor volume involve eloquent brain ( speech/language cortex , motor/sensory cortex , basal ganglion , brainstem , corpus callosum ) . 3 . Concurrent treatment chemotherapy . 4 . Active infectious process require IV antibiotic . 5 . History cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum three year . 6 . Other major medical illness judge investigator preclude prolong followup . 7 . Any condition compromise compliance objective procedure protocol , judge principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Gamma Knife radiosurgery</keyword>
	<keyword>recurrent glioma</keyword>
	<keyword>MRI</keyword>
	<keyword>Spectroscopy</keyword>
	<keyword>Recurrent grade IV glioma ( glioblastoma ) , two additional exploratory arm patient recurrent grade II grade III glioma</keyword>
</DOC>